Search Within

Dana Elizabeth Rathkopf

Formats
  1. Meeting Abstract (161)
  2. Journal Article (106)
  3. Review (4)
  4. Editorial (3)
  5. Correspondence (1)
Groups
  1. Department of Medicine (275)
  2. Genitourinary Oncology Service (275)
  3. Solid Tumor Oncology Division (275)
  4. Hematologic Malignancies, Division of (70)
  5. GSK Faculty (53)
  6. Human Oncology and Pathogenesis Program (41)

More Groups

People
  1. Howard Scher (133)
  2. Michael Morris (79)
  3. Susan Slovin (59)
  4. Daniel Danila (45)
  5. Karen Autio (34)
  6. Wassim Abida (31)

More People

Years
  1. 2025 (11)
  2. 2024 (20)
  3. 2023 (19)
  4. 2022 (16)
  5. 2021 (18)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (122)
  2. Annals of Oncology (27)
  3. European Urology (16)
  4. Clinical Cancer Research (13)
  5. Cancer Research (9)
  6. European Journal of Cancer (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (125)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (26)
  4. Elsevier Science, Inc. (24)
  5. Elsevier Inc. (16)
  6. Nature Publishing Group (9)

More Publishers

Results (275)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: A systematic review
    Review

    Francini, E.; Agarwal, N.; Castro, E.; Cheng, H. H.; Chi, K. N.; Clarke, N.; Mateo, J.; Rathkopf, D.; Saad, F.; Tombal, B.
    European Urology (2025)

    Fulltext@MSK | Save
  • SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
    Meeting Abstract

    Rathkopf, D.; Dallos, M.; Stein, M.; Spina, C. S.; Deutsch, I.; Nguyen, C.; Okada, A.; Lloyd, M.; Manarite, J.; McBride, S.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castrationresistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N. J.; Hawley, J.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes in patients with metastatic castration-resistant prostate cancer and BRCA1/2 mutations receiving first-line niraparib with abiraterone acetate plus prednisone (Magnitude study)
    Meeting Abstract

    Nguyen, C.; Rathkopf, D. E.; Chi, K. N.; Small, E.; Smith, M.
    Oncology Nursing Forum (2024)

    Fulltext@MSK | Save
  • Final analysis of patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations receiving first-line niraparib with abiraterone acetate plus prednisone (MAGNITUDE Study) for cancer caregivers: A pilot to address existential distress in caregivers of hematopoietic stem cell transplant patients
    Meeting Abstract

    Olivier, K.; Smith, M.; Rathkopf, D. E.; Small, E.; Guckert, M.; Chi, K. N.
    Oncology Nursing Forum (2024)

    Fulltext@MSK | Save
  • Long-term patient-reported health-related quality of life in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH Agonist with either bicalutamide or abiraterone acetate plus prednisone and apalutamide after radical prostatectomy
    Meeting Abstract

    Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; Bubley, G.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Testosterone Recovery and Associated Impact on PatientReported Health -Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
    Meeting Abstract

    Moningi, S.; Nguyen, P. L.; Rathkopf, D.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; Bubley, G.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Androgen deprivation therapy drives a distinct immune phenotype in localized prostate cancer
    Journal Article

    Dallos, M. C.; Obradovic, A. Z.; McCann, P.; Chowdhury, N.; Pratapa, A.; Aggen, D. H.; Gaffney, C.; Autio, K. A.; Virk, R. K.; De Marzo, A. M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design
    Meeting Abstract

    Azad, A.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Rathkopf, D. E.; Runcie, K.; Zhang, T.; Pruthi, R.; Bhaumik, A.; Mundle, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save